Lv3
345 积分 2024-08-05 加入
PD16-02 INSIGHTS FROM THE PIONEER+ BIG DATA CONSORTIUM FOR PROSTATE CANCER: BASELINE CHARACTERISTICS AND MEDICATION PROFILE VARIATIONS IN MHSPC
9天前
已完结
PD16-02 INSIGHTS FROM THE PIONEER+ BIG DATA CONSORTIUM FOR PROSTATE CANCER: BASELINE CHARACTERISTICS AND MEDICATION PROFILE VARIATIONS IN MHSPC
9天前
已关闭
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
1个月前
已完结
Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores
2个月前
已完结
心理干预对前列腺癌根治术后尿失禁患者心理状态和生活质量的影响
2个月前
已完结
临床试验中疗效指标观察与测量相关问题的考虑
2个月前
已完结
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison
2个月前
已完结
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
2个月前
已关闭
Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)
2个月前
已完结
Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)
2个月前
已完结
皖公网安备34019202002308
